THIOREDOXIN 1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING THERETO

Title:

THIOREDOXIN 1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING THERETO

Document Type and Number:

WIPO Patent Application WO/2019/074333

Kind Code:

A2

Abstract:

The present invention relates to an epitope of a thioredoxin-1 (Trx1) antigen and a use thereof and, more specifically, provides the epitope and an antibody or antigen-binding fragment that binds thereto. An epitope region of a human Trx1 antigen identified in the present invention can be usefully utilized for developing an improved antibody for improving the binding affinity of an anti-Trx1 antibody. In addition, the improved antibody of the present invention is superior to existing anti-Trx1 antibodies in terms of the binding affinity to thioredoxin 1 and has very high levels of sensitivity and specificity, thereby being useful for improving the performance of a breast cancer diagnostic kit. Furthermore, detection of thioredoxin 1 using an antibody that specifically binds to thioredoxin 1 of the present invention is far superior in sensitivity and specificity to detection of the existing breast cancer diagnostic biomarker CA15-3, and thus the accuracy and reliability of diagnosis of breast cancer can be remarkably improved.

Inventors:

SUH KYONG HOON (KR)
KIM DAE JOONG (KR)
KIM YOUNG (KR)
KIM MI KYUNG (KR)
JUNG JONG HWAN (KR)
LEE KI SE (KR)

Application Number:

PCT/KR2018/012069

Publication Date:

April 18, 2019

Filing Date:

October 12, 2018

Export Citation:

Click for automatic bibliography generation Help

Assignee:

E&S HEALTHCARE CO LTD (KR)

International Classes:

C07K7/06

Foreign References:

KR101058230B1

2011-08-22

Other References: